Bio-Techne

Q3 2026 in 1mo Q2 2026 +4.80%Q1 2026 -1.95%Q4 2025 -8.73%Q3 2025 +2.20%Q2 2025 +3.72%Q1 2025 +4.26%Q4 2024 -6.44%Q3 2024 +19.60%Q2 2024 -6.17%Q1 2024 -6.73%Q4 2023 +2.10%Q3 2023 +4.78%Q2 2023 -2.61%Q1 2023 +0.57%Q4 2022 -2.27%Q3 2022 +0.71%Q2 2022 +11.02%Q1 2022 -3.95%Q4 2021 -1.01%Q3 2021 +1.50%Q2 2021 +8.33%Q1 2021 +13.22%Q4 2020 -3.94%Q3 2020 +7.75%Q2 2020 -0.29%Q1 2020 0.00%Q4 2019 -4.55%Q3 2019 +3.00%Q2 2019 +5.31%Q1 2019 -5.50%Q4 2018 +5.02%Q3 2018 -2.84%Q2 2018 +2.96%Q1 2018 +3.85%Q4 2017 -1.55%Q3 2017 +2.01%Q2 2017 -1.03%Q1 2017 +0.28%Q4 2016 -3.37%Q3 2016 +7.12%Q2 2016 +4.94%Q1 2016 -8.96%Q4 2015 -2.34%Q3 2015 +1.57%Q2 2015 -3.22%Q1 2015 -2.84%Q4 2014 +0.21%Q3 2014 +8.11%Q2 2014 -4.38%Q1 2014 +0.73%Q4 2013 +4.07%Q3 2013 +0.37%Q2 2013 -2.15%Q1 2013 -4.25%Q4 2012 -3.85%Q3 2012 +0.46%Q2 2012 +2.18%Q1 2012 -5.34%Q4 2009 +1.41%Q4 2011 +1.41%Q3 2010 +0.51%Q3 2011 +0.51%Q2 2011 -0.76%Q1 2010 +0.60%Q1 2011 +0.60%Q2 2010 +0.60%Q4 2010 +0.60%

Aug 07, 2024

•

Jun 30, 2024

Bio-Techne Q4 2024 Earnings Report

Bio-Techne's Q4 2024 financial performance reflected solid results amidst stabilizing end-markets.

Key Takeaways

Bio-Techne reported a 2% increase in net sales for the fourth quarter of fiscal year 2024, reaching $306.1 million. GAAP EPS was $0.25, while adjusted EPS was $0.49. The Diagnostics & Genomics segment showed strong growth, with a 15% increase in net sales.

Organic revenue increased by 1% (2% reported) to $306.1 million.

GAAP EPS was $0.25 versus $0.47 one year ago; adjusted EPS was $0.49 compared to $0.55 one year ago.

Diagnostics & Genomics segment achieved 9% organic growth (15% reported).

Adjusted operating margin was 33.5%, representing a 50 basis-point sequential improvement.